Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-1: Tavapadon Fixed-Dose Trial in Early Parkinson's Disease
2019-002949-38Phase 3Terminated
- Sponsor
- Cerevel Therapeutics
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tavapadon in Parkinson's disease (PD) (3 arms), sponsored by Cerevel Therapeutics. Primary endpoint: Primary efficacy endpoint. Started Dec 2019; status: terminated.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-002949-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002949-38.